Early Detection and Prevention of Cognitive Disorders: Neuro-Biotech Corp`s NeuroChAT explained

BASEL, Switzerland, Oct. 29 /PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES), pursuant to the company's press release issued the 4th of october 2010, the following is a brief review and explanation of the earlier statements concerning NeuroChAT also known as Neuro-Bio Test #8 (formerly GACHA), which is able to quantitatively measure the enzyme related to the synthesis of acetylcholine, a neurotransmitter involved in cognitive disorders like Alzheimer Disease.

Neuro-Biotech Corp. has developed a test unlike no other. It enables the detection of Alzheimers Disease in its earliest stages. The company intends to offer relevant tests for people between 35 and 55 years of age to quickly focus on a proper diagnosis. It is vitally important to be able to distinguish between "Vascular cognitive disorders (VCD)," "Psychosis," "Senility," and "Dementia" (related to ageing). Thus by targeting patients with appropriate therapeutic treatments, this allows doctors to provide a better quality of care for their patients. Neuro-Biotech Corp. shall encourage this beneficial "doctor-patient" relationship at all times. Moreover, Medical practitioners will be able to properly diagnose their patients and start an early treatment with continued follow up in order to report the initial symptoms and consequent damages.

It is important to note that when undergoing a progressive clinical investigation involving the input and output of the brain, the relationship between the brain, the adrenals and the immune system has to be taken into account.  In this respect, quantitative measurement of the enzyme acetylcholine of the main neurotransmitter involved in AD will present clinical indications on the course of action to undertake.

It is well known that Alzheimer's Disease (AD) is a progressive neurodegenerative disease that can begin as early as the age of 30 (according to World Health Organization (WHO)) due to medical incidents such as cerebral shock (concussion), cerebral vascular accidents, drugs abuses, and severe depression. Last year's World Alzheimer Report estimated that there are 35.6 million people living with dementia worldwide in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050. Furthermore, this Report mentions that the associated costs are presently evaluated at 604 Billion US dollars.

Neuro-Biotech Corp. will be able to prevent, and defer the symptoms related to all the cognitive disorders and to improve the quality of life through continuous follow-ups.

For more information, do not hesitate to contact us by using the contact form on our corporate website at neuro-biotechcorp.com. Your request will be transferred to the appropriate persons and we will get back to you as soon as possible.

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

CONTACT:

Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
[e-mail]
www.neuro-biotechcorp.com

SOURCE Neuro-Biotech Corp.

Copyright . 29 PR Newswire